Abstract
Aurora-A, the most widely studied isoform of Aurora kinase overexpressed aberrantly in a wide variety of tumors, has been implicated in early mitotic entry, degradation of natural tumor suppressor p53 and centrosome maturation and separation; hence, potent inhibitors of Aurora-A may be therapeutically useful drugs in the treatment of various forms of cancer. Here, we report an in silico study on a group of 220 reported Aurora-A inhibitors with six different substructures. Three-dimensional quantitative structure–activity relationship (3D-QSAR) studies were carried out using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques on this series of molecules. The resultant optimum 3D-QSAR models exhibited an r 2cv value of 0.404-0.582 and their predictive ability was validated using an independent test set, ending in r 2pred 0.512-0.985. In addition, docking studies were employed to explore these protein–inhibitor interactions at the molecular level. The results of 3D-QSAR and docking analyses validated each other, and the key structural requirements affecting Aurora-A inhibitory activities, and the influential amino acids involved were identified. To the best of our knowledge, this is the first report on 3D-QSAR modeling of Aurora-A inhibitors, and the results can be used to accurately predict the binding affinity of related analogues and also facilitate the rational design of novel inhibitors with more potent biological activities.
Similar content being viewed by others
References
Fu J, Bian M, Jiang Q, Zhang C (2007) Mol Cancer Res 5:1–10
Keen N, Taylor S (2004) Nat Rev Cancer 4:927–936
Andrews PD (2005) Oncogene 24:5005–5015
Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Nat Rev Cancer 7:107–117
Giet R, Petretti C, Prigent C (2005) Trends Cell Biol 15:241–250
Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Cell 81:95–105
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CSM, Novotny M, Salomon DJ, Plowman GD (1998) EMBO J 17:3052–3065
Pollard JR, Mortimore M (2009) J Med Chem 52:2629–2651
Andersen CB, Wan Y, Chang JW, Riggs B, Lee C, Liu Y, Sessa F, Villa F, Kwiatkowski N, Suzuki M, Nallan L, Heald R, Musacchio A, Gray NS (2008) ACS Chem Biol 3:180–192
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Nat Genet 20:189–193
Dutertre S, Descamps S, Prigent C (2002) Oncogene 21:6175–6183
Barr AR, Gergely F (2007) J Cell Sci 120:2987–2996
Giet R, Uzbekov R, Cubizolles F, Le Guellec K, Prigent C (1999) J Biol Chem 274:15005–15013
Bolanos-Garcia VM (2005) Int J Biochem Cell Biol 37:1572–1577
Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ (2004) J Biol Chem 279:52175–52182
Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A (2007) Cancer Biol Ther 6:525–533
Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ (2003) Clin Cancer Res 9:1420–1426
Li DH, Zhu JJ, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S (2003) Clin Cancer Res 9:991–997
Reiter R, Gais P, Jutting U, Steuer-Vogt MK, Pickhard A, Bink K, Rauser S, Lassmann S, Höfler H, Werner M, Walch A (2006) Clin Cancer Res 12:5136–5141
Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX (2006) Oncogene 25:7148–7158
Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) J Cell Biol 161:267–280
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JMC, Miller KM (2004) Nat Med 10:262–267
Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM (2003) J Cell Biol 161:281–294
Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, Savi CD, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S (2007) J Med Chem 50:2213–2224
Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, Leroy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF (2007) Proc Natl Acad Sci USA 104:4106–4111
Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y (2010) Mol Cancer Ther 9:157–166
Bebbington D, Binch H, Charrier JD, Everitt S, Fraysse D, Golec J, Kay D, Knegtel R, Mak C, Mazzei F, Miller A, Mortimore M, O’Donnell M, Patel S, Pierard F, Pinder J, Pollard J, Ramaya S, Robinson D, Rutherford A, Studley J, Westcott J (2009) Bioorg Med Chem Lett 19:3586–3592
Coumar MS, Leou JS, Shukla P, Wu JS, Dixit AK, Lin WH, Chang CY, Lien TW, Tan UK, Chen CH, Hsu JT, Chao YS, Wu SY, Hsieh HP (2009) J Med Chem 52:1050–1062
Anderson K, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Patrick D, Silva D, Tummino PJ, Copeland RA, Lai Z (2007) Biochemistry 46:10287–10295
Cramer RD III, Patterson DE, Bunce JD (1988) J Am Chem Soc 110:5959–5967
Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130–4146
Wang YH, Li Y, Yang SL, Yang L (2005) J Comput Aided Mol Des 19:137–147
Li Y, Wang YH, Yang L, Zhang SW, Liu CH (2006) Internet Electron J Mol Des 5:1–12
Xu X, Yang W, Li Y, Wang YH (2010) Expert Opin Drug Discov 5:21–31
Li Y, Wang YH, Yang L, Zhang SW, Liu CH, Yang SL (2005) J Mol Struct 733:111–118
Ai CZ, Wang YH, Li Y, Li YH, Yang L (2008) QSAR Comb Sci 27:1183–1192
Aliagas-Martin I, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Huang OW, Hunsaker T, Kleinheinz T, Krueger E, Liang J, Moffat J, Phillips G, Pulk R, Rawson TE, Ultsch M, Walker L, Wiesmann C, Zhang B, Zhu BY, Cochran AG (2009) J Med Chem 52:3300–3307
Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O’Brien MA, O’Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovi M, Wyatt PG (2009) J Med Chem 52:379–388
Rawson TE Rüth M, Blackwood E, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Georges GJ, Goller B, Halladay J, Hunsaker T, Kleinheinz T, Krell HW, Li J, Liang J, Limberg A, McNutt A, Moffat J, Phillips G, Ran Y, Safina B, Ultsch M, Walker L, Wiesmann C, Zhang B, Zhou A, Zhu BY, Ru¨ger P, Cochran AG (2008) J Med Chem 51:4465–4475
Heron NM, Anderson M, Blowers DP, Breed J, Eden JM, Green S, Hill GB, Johnson T, Jung FH, McMiken HH, Mortlock AA, Pannifer AD, Pauptit RA, Pink J, Roberts NJ, Rowsell S (2006) Bioorg Med Chem Lett 16:1320–1323
Jung FH, Pasquet G, Lambert-van der Brempt C, Lohmann JJ, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S (2006) J Med Chem 49:955–970
Leonard JT, Roy K (2006) QSAR Comb Sci 25:235–251
Jain AN (2003) J Med Chem 46:499–511
Zhao B, Smallwood A, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Lai Z (2008) Protein Sci 17:1791–1797
Tari LW, Hoffman ID, Bensen DC, Hunter MJ, Nix J, Nelson KJ, McRee DE, Swanson RV (2007) Bioorg Med Chem Lett 17:688–691
Cheetham GM, Knegtel RM, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA, Austen DA (2002) J Biol Chem 277:42419–42422
Roy PP, Roy K (2008) QSAR Comb Sci 27:302–313
Acknowledgments
This work is supported financially by the National Natural Science Foundation of China (Grant No. 10801025) and the Fund of Northwest A&F University. We thank Dr. Ming Hao for helping with PCA analysis.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Materials
Below is the link to the electronic supplementary material.
ESM 1
Supporting information is available on the publishers Web site along with the published article. (PDF 6933 kb)
Rights and permissions
About this article
Cite this article
Zhang, Hx., Li, Y., Wang, X. et al. Probing the structural requirements of A-type Aurora kinase inhibitors using 3D-QSAR and molecular docking analysis. J Mol Model 18, 1107–1122 (2012). https://doi.org/10.1007/s00894-011-1042-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-011-1042-3